Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Consolidated Net Income (2020 - 2025)

Historic Consolidated Net Income for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$34.0 million.

  • Lyell Immunopharma's Consolidated Net Income rose 2369.33% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 7161.37%. This contributed to the annual value of -$334.7 million for FY2024, which is 4971.13% down from last year.
  • Per Lyell Immunopharma's latest filing, its Consolidated Net Income stood at -$34.0 million for Q3 2025, which was up 2369.33% from -$43.9 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Consolidated Net Income ranged from a high of -$11.3 million in Q4 2022 and a low of -$196.2 million during Q4 2024
  • Moreover, its 5-year median value for Consolidated Net Income was -$52.4 million (2023), whereas its average is -$57.0 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first soared by 7600.13% in 2022, then tumbled by 36266.0% in 2023.
  • Over the past 5 years, Lyell Immunopharma's Consolidated Net Income (Quarter) stood at -$47.2 million in 2021, then surged by 76.0% to -$11.3 million in 2022, then crashed by 362.66% to -$52.4 million in 2023, then crashed by 274.31% to -$196.2 million in 2024, then skyrocketed by 82.68% to -$34.0 million in 2025.
  • Its last three reported values are -$34.0 million in Q3 2025, -$43.9 million for Q2 2025, and -$53.5 million during Q1 2025.